← Back to Search

Behavioral Intervention

Cognitive-Behavioral Therapy for ADHD in College Students (ADHD Trial)

N/A
Recruiting
Led By Mary V. Solanto, Ph.D.
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline brief-a at 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will help college students with ADHD develop skills to succeed in their studies and avoid negative academic outcomes.

Who is the study for?
This trial is for college students at The City College of New York who have been diagnosed with ADHD, either Inattentive or Combined Subtype. Participants should be in good physical health. It's not open to individuals who are actively suicidal, have certain psychiatric disorders like bipolar disorder or borderline personality disorder, a history of severe childhood trauma, neurological issues, recent drug or alcohol abuse, or any acute psychiatric condition that requires immediate treatment.
What is being tested?
The study is testing a cognitive-behavioral therapy program designed to help college students with ADHD improve their self-management skills. This includes better time management and planning to enhance academic performance and reduce the likelihood of negative educational outcomes.
What are the potential side effects?
Since this trial involves psychological therapy rather than medication, traditional side effects associated with drugs are not expected. However, participants may experience emotional discomfort discussing personal issues during therapy sessions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline aisrs at six months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline aisrs at six months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from Baseline Adult Investigator Symptom Rating Scale (AISRS) at six months
Change from Baseline Behavior Rating Scale of Executive Function - Adult Version (BRIEF-A) at six months
Change from Baseline Learning and Study Strategies Inventory (LASSI) at six months

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cognitive Behavioral Therapy delivered in a group formatExperimental Treatment1 Intervention
Participating students will be assessed before and after the 12-week group Cognitive-Behavioral intervention to ascertain their response to the treatment.

Find a Location

Who is running the clinical trial?

Northwell HealthLead Sponsor
474 Previous Clinical Trials
469,092 Total Patients Enrolled
2 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
525 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
The City College of New YorkOTHER
29 Previous Clinical Trials
6,574 Total Patients Enrolled
Mary V. Solanto, Ph.D.Principal InvestigatorNorthwell Health
Anthony Rostain, M.D.Principal InvestigatorCooper School of Medicine at Rowan University

Media Library

Cognitive-Behavioral Therapy Targeting Executive Dysfunction in College Students with ADHD (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05588505 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Cognitive Behavioral Therapy delivered in a group format
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: Cognitive-Behavioral Therapy Targeting Executive Dysfunction in College Students with ADHD Highlights & Side Effects. Trial Name: NCT05588505 — N/A
Cognitive-Behavioral Therapy Targeting Executive Dysfunction in College Students with ADHD (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05588505 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Patient Testimony for trial: Trial Name: NCT05588505 — N/A
~13 spots leftby Dec 2025